Comparative metabolism of aschantin in human and animal hepatocytes
In conclusion, aschantin is extensively metabolized, producing 18 metabolites in human and animal hepatocytes catalyzed by CYP, COMT, UDP-glucuronosyltransferase, and sulfotransferase. These results can help in clarifying the involvement of metabolizing enzymes in the pharmacokinetics and drug interactions of aschantin and in elucidating GSH conjugation associated with the reactive intermediate formed from M1 (aschantin catechol).PMID:38182943 | DOI:10.1007/s12272-023-01483-w (Source: Archives of Pharmacal Research)
Source: Archives of Pharmacal Research - January 5, 2024 Category: Drugs & Pharmacology Authors: Min Seo Lee Hyun Joo Shim Yong-Yeon Cho Joo Young Lee Han Chang Kang Im-Sook Song Hye Suk Lee Source Type: research
Comparative metabolism of aschantin in human and animal hepatocytes
In conclusion, aschantin is extensively metabolized, producing 18 metabolites in human and animal hepatocytes catalyzed by CYP, COMT, UDP-glucuronosyltransferase, and sulfotransferase. These results can help in clarifying the involvement of metabolizing enzymes in the pharmacokinetics and drug interactions of aschantin and in elucidating GSH conjugation associated with the reactive intermediate formed from M1 (aschantin catechol).PMID:38182943 | DOI:10.1007/s12272-023-01483-w (Source: Archives of Pharmacal Research)
Source: Archives of Pharmacal Research - January 5, 2024 Category: Drugs & Pharmacology Authors: Min Seo Lee Hyun Joo Shim Yong-Yeon Cho Joo Young Lee Han Chang Kang Im-Sook Song Hye Suk Lee Source Type: research
Comparative metabolism of aschantin in human and animal hepatocytes
In conclusion, aschantin is extensively metabolized, producing 18 metabolites in human and animal hepatocytes catalyzed by CYP, COMT, UDP-glucuronosyltransferase, and sulfotransferase. These results can help in clarifying the involvement of metabolizing enzymes in the pharmacokinetics and drug interactions of aschantin and in elucidating GSH conjugation associated with the reactive intermediate formed from M1 (aschantin catechol).PMID:38182943 | DOI:10.1007/s12272-023-01483-w (Source: Archives of Pharmacal Research)
Source: Archives of Pharmacal Research - January 5, 2024 Category: Drugs & Pharmacology Authors: Min Seo Lee Hyun Joo Shim Yong-Yeon Cho Joo Young Lee Han Chang Kang Im-Sook Song Hye Suk Lee Source Type: research
Comparative metabolism of aschantin in human and animal hepatocytes
In conclusion, aschantin is extensively metabolized, producing 18 metabolites in human and animal hepatocytes catalyzed by CYP, COMT, UDP-glucuronosyltransferase, and sulfotransferase. These results can help in clarifying the involvement of metabolizing enzymes in the pharmacokinetics and drug interactions of aschantin and in elucidating GSH conjugation associated with the reactive intermediate formed from M1 (aschantin catechol).PMID:38182943 | DOI:10.1007/s12272-023-01483-w (Source: Archives of Pharmacal Research)
Source: Archives of Pharmacal Research - January 5, 2024 Category: Drugs & Pharmacology Authors: Min Seo Lee Hyun Joo Shim Yong-Yeon Cho Joo Young Lee Han Chang Kang Im-Sook Song Hye Suk Lee Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict pitavastatin pharmacokinetics according to SLCO1B1 genetic polymorphism. PK-Sim® version 10.0 was used to establish the whole-body PBPK model of pitavastatin. Our pharmacogenomic data and a total of 27 clinical pharmacokinetic data with different dose administration and demographic properties were used to develop and validate the model, respectively. Physicochemical properties and disposition characteristics of pitavastatin were acquired from previously reported data or optimized to capture the plasma concentration-time profile...
Source: Archives of Pharmacal Research - December 30, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Ju Yeon Mo Eunvin Ko Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict pitavastatin pharmacokinetics according to SLCO1B1 genetic polymorphism. PK-Sim® version 10.0 was used to establish the whole-body PBPK model of pitavastatin. Our pharmacogenomic data and a total of 27 clinical pharmacokinetic data with different dose administration and demographic properties were used to develop and validate the model, respectively. Physicochemical properties and disposition characteristics of pitavastatin were acquired from previously reported data or optimized to capture the plasma concentration-time profile...
Source: Archives of Pharmacal Research - December 30, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Ju Yeon Mo Eunvin Ko Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism
This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict pitavastatin pharmacokinetics according to SLCO1B1 genetic polymorphism. PK-Sim® version 10.0 was used to establish the whole-body PBPK model of pitavastatin. Our pharmacogenomic data and a total of 27 clinical pharmacokinetic data with different dose administration and demographic properties were used to develop and validate the model, respectively. Physicochemical properties and disposition characteristics of pitavastatin were acquired from previously reported data or optimized to capture the plasma concentration-time profile...
Source: Archives of Pharmacal Research - December 30, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Ju Yeon Mo Eunvin Ko Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Arch Pharm Res. 2023 Dec 28. doi: 10.1007/s12272-023-01479-6. Online ahead of print.ABSTRACTThe emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. Various ADCs have been licensed for clinical usage, with ongoing research paving the way for additional options. However, the manufacture of ADCs faces several challenges. These i...
Source: Archives of Pharmacal Research - December 28, 2023 Category: Drugs & Pharmacology Authors: Shivangi Kumari Sonam Raj M Arockia Babu Gurjit Kaur Bhatti Jasvinder Singh Bhatti Source Type: research
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Arch Pharm Res. 2023 Dec 28. doi: 10.1007/s12272-023-01479-6. Online ahead of print.ABSTRACTThe emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. Various ADCs have been licensed for clinical usage, with ongoing research paving the way for additional options. However, the manufacture of ADCs faces several challenges. These i...
Source: Archives of Pharmacal Research - December 28, 2023 Category: Drugs & Pharmacology Authors: Shivangi Kumari Sonam Raj M Arockia Babu Gurjit Kaur Bhatti Jasvinder Singh Bhatti Source Type: research
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Arch Pharm Res. 2023 Dec 28. doi: 10.1007/s12272-023-01479-6. Online ahead of print.ABSTRACTThe emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. Various ADCs have been licensed for clinical usage, with ongoing research paving the way for additional options. However, the manufacture of ADCs faces several challenges. These i...
Source: Archives of Pharmacal Research - December 28, 2023 Category: Drugs & Pharmacology Authors: Shivangi Kumari Sonam Raj M Arockia Babu Gurjit Kaur Bhatti Jasvinder Singh Bhatti Source Type: research
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Arch Pharm Res. 2023 Dec 28. doi: 10.1007/s12272-023-01479-6. Online ahead of print.ABSTRACTThe emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. Various ADCs have been licensed for clinical usage, with ongoing research paving the way for additional options. However, the manufacture of ADCs faces several challenges. These i...
Source: Archives of Pharmacal Research - December 28, 2023 Category: Drugs & Pharmacology Authors: Shivangi Kumari Sonam Raj M Arockia Babu Gurjit Kaur Bhatti Jasvinder Singh Bhatti Source Type: research
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Arch Pharm Res. 2023 Dec 28. doi: 10.1007/s12272-023-01479-6. Online ahead of print.ABSTRACTThe emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. Various ADCs have been licensed for clinical usage, with ongoing research paving the way for additional options. However, the manufacture of ADCs faces several challenges. These i...
Source: Archives of Pharmacal Research - December 28, 2023 Category: Drugs & Pharmacology Authors: Shivangi Kumari Sonam Raj M Arockia Babu Gurjit Kaur Bhatti Jasvinder Singh Bhatti Source Type: research
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
In this study, we aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics of pantoprazole in populations with various CYP2C19 metabolic activities. A comprehensive investigation of previous reports and drug databases was conducted to collect the clinical pharmacogenomic data, physicochemical data, and disposition properties of pantoprazole, and the collected data were used for model establishment. The model was evaluated by comparing the predicted plasma concentration-time profiles and/or pharmacokinetic parameters (AUC and Cmax) with the clinical observation results. The p...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Eunvin Ko Ju Yeon Mo Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Dysregulation of histone deacetylases in ocular diseases
Arch Pharm Res. 2023 Dec 27. doi: 10.1007/s12272-023-01482-x. Online ahead of print.ABSTRACTOcular diseases are a growing global concern and have a significant impact on the quality of life. Cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy are the most prevalent ocular diseases. Their prevalence and the global market size are also increasing. However, the available pharmacotherapy is currently limited. These diseases share common pathophysiological features, including neovascularization, inflammation, and/or neurodegeneration. Histone deacetylases (HDACs) are a class of enzymes that catalyze ...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Jae Hyun Jun Jun-Sik Kim Leon F Palomera Dong-Gyu Jo Source Type: research
Gastric cancer and mesenchymal stem cell-derived exosomes: from pro-tumorigenic effects to anti-cancer vehicles
Arch Pharm Res. 2023 Dec 27. doi: 10.1007/s12272-023-01477-8. Online ahead of print.ABSTRACTGastric cancer (GC) is one of the most prevalent malignancies in the world, with a high mortality rate in both women and men. Conventional treatments, like chemotherapy, radiotherapy and surgery, are facing some drawbacks like acquired drug resistance and various side effects, leading to cancer recurrence and increased morbidity; thus, development of novel approaches in targeted therapy would be very beneficial. Exosomes, extracellular vesicles with a size distribution of sub-150 nm, interplay in physiological and pathophysiological...
Source: Archives of Pharmacal Research - December 27, 2023 Category: Drugs & Pharmacology Authors: Maryam Dolatshahi Ahmad Reza Bahrami Qaiser Iftikhar Sheikh Mohsen Ghanbari Maryam M Matin Source Type: research
